Published in Eur Urol on January 01, 1998
Histopathological image analysis: a review. IEEE Rev Biomed Eng (2009) 6.86
Upgrading of Gleason score on radical prostatectomy specimen compared to the pre-operative needle core biopsy: an Indian experience. Indian J Urol (2010) 1.69
Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol (2001) 1.23
Prognostic factors in prostate cancer. Diagn Pathol (2006) 0.99
Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging. Clinics (Sao Paulo) (2011) 0.78
Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens. Clinics (Sao Paulo) (2013) 0.75
Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol (1999) 0.75
Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria. Prostate Int (2016) 0.75
Pathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology? Curr Urol (2013) 0.75
Gleason grading challenges in the diagnosis of prostate adenocarcinoma: experience of a single institution. Virchows Arch (2015) 0.75
[Regressive changes after short-term neoadjuvant antihormonal therapy in prostatic carcinoma: the value of Gleason grading]. Pathologe (2006) 0.75
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med (1998) 6.44
Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology (1998) 3.81
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology (1996) 3.29
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol (2001) 2.83
Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol (1998) 2.18
Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU Int (2003) 2.05
Percutaneous stone manipulation. J Urol (1981) 2.00
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol (2000) 1.94
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract (2007) 1.88
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol (1999) 1.86
Proposed cutoff values to define bladder outlet obstruction in women. Urology (1998) 1.76
Is transurethral resection of the prostate still justified? BJU Int (1999) 1.69
Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. J Urol (1998) 1.67
Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res (1995) 1.65
Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol (1999) 1.63
A multicenter, double-blind, randomized, parallel group study comparing polyvinyl chloride and polyvinyl chloride-free catheter materials. J Urol (2009) 1.63
High-grade prostate cancer is associated with low serum testosterone levels. Prostate (2001) 1.59
Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest (1992) 1.57
Morbidity of the evaluation of the lower urinary tract with transurethral multichannel pressure-flow studies. J Urol (1998) 1.51
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology (2001) 1.49
Diagnostic accuracy of DNA image cytometry and urinary cytology with cells from voided urine in the detection of bladder cancer. Urology (2000) 1.38
Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol (1994) 1.26
Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol (1996) 1.22
Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol (1998) 1.21
Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol (1997) 1.21
Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology (1999) 1.18
The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol (2001) 1.17
Morphology of tissue destruction induced by focused ultrasound. Eur Urol (1993) 1.13
Urolithiasis in allograft kidneys. Urology (2002) 1.13
The aging lower urinary tract: a comparative urodynamic study of men and women. Urology (1998) 1.13
Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol (1999) 1.13
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol (2001) 1.11
Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. Br J Urol (1994) 1.11
High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol (1995) 1.10
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol (1997) 1.09
Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol (1998) 1.09
Insulin-like growth factors and prostate cancer. World J Urol (2001) 1.09
The impact of intense laparoscopic skills training on the operative performance of urology residents. J Urol (2001) 1.08
Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol (1998) 1.07
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem (1996) 1.06
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. Urology (2001) 1.06
Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. J Urol (2000) 1.06
PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology (1999) 1.05
Late sequelae of the management of ureteral calculi with the ureterorenoscope. J Urol (1986) 1.05
Embryological and diagnostic aspects of seminal vesicle cysts associated with upper urinary tract malformation. J Urol (1986) 1.03
Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology (2000) 1.03
Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol (1998) 1.02
Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int (2004) 1.01
Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology (1999) 1.00
Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology (1999) 1.00
Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate (2001) 1.00
Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol (1999) 1.00
Transrenal ureteral embolization. Radiology (1979) 0.99
Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer (2001) 0.99
Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate (2001) 0.99
Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia. J Urol (1999) 0.98
Transcatheter embolization of the kidney with butyl-2-cyanoacrylate: experimental and clinical results. Cardiovasc Radiol (1978) 0.98
Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol (1994) 0.98
mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res (2000) 0.98
Spontaneous nontraumatic rupture of a contracted kidney with subcapsular and perirenal hematoma in a patient receiving chronic hemodialysis. Urology (1997) 0.98
Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis (2010) 0.97
Interrelationships of bladder compliance with age, detrusor instability, and obstruction in elderly men with lower urinary tract symptoms. Neurourol Urodyn (1999) 0.97
The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology (1998) 0.96
Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology (2003) 0.95
Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol (2000) 0.95
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology (2001) 0.95
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol (1999) 0.95
Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. J Urol (1998) 0.94
Intracavernous injection of prostaglandin E1 in impotent men. J Urol (1988) 0.94
Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract (2011) 0.93
Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology (2001) 0.92
Modified laparoscopic nephroureterectomy for treatment of upper urinary tract transitional cell cancer is not associated with an increased risk of tumour recurrence. Eur Urol (2003) 0.92
Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol (2004) 0.92
Prostatic tissue ablation by transrectal high intensity focused ultrasound: histological impact and clinical application. Ultrason Sonochem (1997) 0.92
Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms? Br J Urol (1997) 0.92
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J Urol (1999) 0.92
Intrarenal access: effects on renal function and morphology. Br J Urol (1980) 0.91
Is one set of sextant biopsies enough to rule out prostate Cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol (2000) 0.91
Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol (1993) 0.91
Health care in Austria. Universal access, national health insurance, and private health care. JAMA (1993) 0.91
Benign prostatic hyperplasia. BMJ (2001) 0.90
Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate. J Urol (1997) 0.90